metaEvidence - overview

button bars forest bayes pooled summary circles


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
endometrial cancer endometrial cancer
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	none	inconclusive results for: deaths (OS); AE (grade 3-5)	suggested 26 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable	-
	dostarlimab plus soC vs. placebo plus SoC	2	suggested 37 % decrease in progression or deaths (PFS)	inconclusive results for: AE (any grade); AE (grade 3-5); AE leading to death (grade 5); AE leading to treatment discontinuation (any grade); SAE (any grade)	statistically conclusive 31 % decrease in deaths (OS) but the degree if certainty is unassessable	-
	durvalumab plus olaparib plus SoC vs. placebo plus SoC	1	none	inconclusive results for: AE (any grade); AE (grade 3-5); AE leading to treatment discontinuation (any grade)	suggested 41 % decrease in deaths (OS) but the degree if certainty is unassessable statistically conclusive 45 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable	-
	durvalumab plus SoC vs. placebo plus SoC	1	none	inconclusive results for: deaths (OS)	statistically conclusive 29 % decrease in progression or deaths (PFS) but the degree if certainty is unassessable	-
	pembrolizumab plus SoC vs. placebo plus SoC	2	none	-	-	-
versus Standard of Care (SoC)
	avelumab plus SoC vs. Standard of Care (SoC)	1	none	inconclusive results for: deaths (OS); progression or deaths (PFS); AE (grade 3-4); AE leading to death (grade 5)	-	-
	pembrolizumab plus lenvatinib vs. Standard of Care (SoC)	2	statistically conclusive 29 % decrease in progression or deaths (PFS)	inconclusive results for: deaths (OS); DOR; AE (any grade); AE (grade 3-5); AE leading to treatment discontinuation (any grade); SAE (any grade)	suggested 44 % decrease in PFS (extension) but the degree if certainty is unassessable suggested 3.0-fold increase in objective responses (ORR) but the degree if certainty is unassessable	-
endometrial cancer - (neo)adjuvant (NA) endometrial cancer - (neo)adjuvant (NA)